[{"id":"f86dd180-9964-44e8-9f7d-13e77891a73a","acronym":"STOPTRAFFIC-1","url":"https://clinicaltrials.gov/study/NCT04599140","created_at":"2021-02-21T15:52:40.898Z","updated_at":"2025-02-25T14:29:40.279Z","phase":"Phase 1/2","brief_title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","source_id_and_acronym":"NCT04599140 - STOPTRAFFIC-1","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • CD8 • CD4 • CD69 • IRF2","pipe":"","alterations":" ","tags":["BRAF • CD8 • CD4 • CD69 • IRF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/14/2020","start_date":" 10/14/2020","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-17"}]